NCT05624918View on ClinicalTrials.gov

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
Pancreatic AdenocarcinomaResectable Pancreatic Cancer
Interventions
DRUG

Nab paclitaxel

125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle

DRUG

Gemcitabine

1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle

DEVICE

NovoTTF-200T(P)

Worn \> 18 hr /day starting C1D1 until completion of cycle 3

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

NovoCure GmbH

INDUSTRY

collaborator

Ohio State University

OTHER

lead

Ashish Manne

OTHER